| Literature DB >> 35493171 |
Xianghui Li1, Shichao Ai1, Xiaofeng Lu1, Song Liu1, Wenxian Guan1.
Abstract
Gastric cancer is the second biggest cause of cancer-related deaths worldwide. Despite the improvement in deciphering molecular mechanisms, advances of detection and imaging, implementation of prevention programs, and personalized treatment, the overall curative rate remains low. In particular, with the emergence of nanomaterials, different imaging modalities can be integrated into one single platform, and combined therapies with synergetic effects against gastric cancer were established. Moreover, the development of theranostic strategies with simultaneous diagnostic and therapeutic ability was boosted by multifunctional nanoparticles. Herein, we present a comprehensive review of major nanotechnology-based breakthroughs for gastric cancer imaging and treatment. We will describe the superiority of nanomaterials used in gastric cancer and summarize nanotechnology applications for the improvement of cancer imaging and therapeutic efficacy. This journal is © The Royal Society of Chemistry.Entities:
Year: 2021 PMID: 35493171 PMCID: PMC9043273 DOI: 10.1039/d1ra01947c
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Fig. 1Nanoparticles designed for gastric cancer theronostics.
Fig. 2(a) Scheme illustration of tumor-targeting and MMP-2 activatable fluorescent nanoprobe (T-MAN), which can selectively enter and accumulate in the gastric tumors via αvβ3 integrin mediated active delivery. (b) Fluorescence image of T-MAN. (c) MR imaging of T-MAN. Reprinted with permission from ref. 78. Copyright 2019, American Chemical Society.
Fig. 3(a) Schematic diagram of the synthetic process of iRGD-W18O49-17AAG. (b) In vivo CT image of iodixanol and iRGD-W18O49-17AAG nanoparticles. (c) In vivo fluorescence image of iRGD-W18O49-17AAG. Reprinted with permission from ref. 83. Copyright 2019, John Wiley and Sons.
Representative nanotechnology-based theranostic agents for gastric cancera
| Nanoparticles | Imaging strategy | Therapeutic strategy | References |
|---|---|---|---|
| ICG-loaded lactosome | Fluorescence | PTT |
|
| Carbon–gold hybrid nanoparticles | Fluorescence | PTT |
|
| Ternary copper-based chalcogenide nanoplatform CuS–NiS2 nanomaterials | MRI | PTT/PDT |
|
| Hyaluronidase-sensitive mesoporous silica nanoparticles | Fluorescence | PDT |
|
| Chlorin e6 functionalized silk fibroin nanoparticles | Fluorescence | Chemotherapy |
|
| Folic acid–sericin–cholesterol/IR780 micelles | Fluorescence | PTT/PDT |
|
| IR820/paclitaxel/imiquimod/encapsulated thermosensitive liposome | Fluorescence | PTT/PDT/chemotherapy |
|
| Cisplatin/ICG loaded PLGA-(DSPE-PEG2000) nanoparticles | Fluorescence | Chemotherapy |
|
| Oxaliplatin–Au–Fe3O4–herceptin nanoparticles | MRI | Chemotherapy |
|
| RGD-CuS-Cy5.5 nanoparticles | CT/MRI | PTT |
|
| W18O49 nanoparticles | CT/fluorescence | PTT |
|
| PEGPCL-IR780-MET nanoparticles | PA/fluorescence | PTT |
|
| PTX-R837-IR820@TSL | Fluorescence | PTT/PDT/chemotherapy/Immunotherapy |
|
| DOX-IR820 nanoparticles | Fluorescence | PTT/chemotherapy |
|
Abbreviations: PA, photoacoustic; PTT, photothermal therapy; PDT, photodynamic therapy.
Fig. 4(a) Schematic illustration of PEG-PCL-IR780-MET NPs. (b) In vivo fluorescence image of PEG-PCL-IR780-MET NPs. (c) Photoacoustic image of PEG-PCL-IR780-MET NPs (d) H&E staining and TUNEL staining tumor sections. Copyright with permission from ref. 68. Copyright 2020 Elsevier.